Thomas Gabrielczyk's articles Biotechnology SLAS: automation start ups set to enable P4 medicine Leroy Hood’s vision of P4 or ‘systemic’ medicine (preventive, predictive, personalised, participatory) is becoming a reality. By using omics data and medical records to create AI-powered individual health profiles, new automated product innovations aim to target diseases before symptoms even appear, reducing healthcare costs. On the second day of the SLAS 2025 conference, SLAS Ignite […] Written by Thomas Gabrielczyk January 29, 2025January 29, 2025 Saving Bookmark this article Bookmarked Biotechnology Merry Christmas and a Happy New Year European Biotechnology wishes its readers a Merry Christmas and a Happy New Year! We are taking a short winter break and will be back in January 2025 to provide you with the latest news, background reports, personalia and – in cooperation with our new partner, the Society for Laboratory Automation & Screening (SLAS) – updates […] Written by Thomas Gabrielczyk December 26, 2024December 26, 2024 Saving Bookmark this article Bookmarked Biotechnology Elevation Oncology Inc licences Synaffix BV’s ADC platform With the US$368m licence deal, Elevation Oncology, Inc is recognising Synaffix’s expertise in ADC development for the development of EO-1022. In contrast to Synaffix’s November deal with the Chinese BigHat Bioscience Co. Ltd, the US company does not book Lonza’s ADC manufacturing services that offers the same quality assurance process for all (clinicla) development phases, […] Written by Thomas Gabrielczyk December 13, 2024December 13, 2024 Saving Bookmark this article Bookmarked Biotechnology Tetraspecific B/NK cell better than T cell engagers The therapeutic landscape for relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) is evolving toward targeted T-cell based immunotherapies, including CD19-targeted CAR-T and CD3xCD20 T-cell engaging (TCE) bispecificantibodies. Yet, there remains an unmet medical need for patients who are refractory to, or ineligible for these treatments. Leveraging natural killer NK cells emerges as a promising […] Written by Thomas Gabrielczyk November 16, 2024November 16, 2024 Saving Bookmark this article Bookmarked Biotechnology Sphingotec secures Series C financing Diagnostics company SphingoTec GmbH (Hennigsdorf, Germany) has successful closed a €5m Series C financing round led by Think.Health Ventures, with support from existing investors Brandenburg Kapital, HBM Healthcare Investments, NRW.BANK, and Wellington Partners. The raised capital will allow the company to reach profitability through partnerships and licence deals of its kidney function test penKid and […] Written by Thomas Gabrielczyk August 15, 2024August 15, 2024 Saving Bookmark this article Bookmarked Biotechnology Gourmey files first EU application for cell-based meat At the time of its EU market authorisation application, Gourmey SAS, which has raised €57.8m so far, has applied for authorisation from the competent authorities in the UK, Switzerland, Singapore and the USA. Ivo Rzegotta, responsible for political communication at GFI Europe interest group, described the application as an important signal for the sector: ‘Cultivated […] Written by Thomas Gabrielczyk July 29, 2024July 29, 2024 Saving Bookmark this article Bookmarked
Biotechnology SLAS: automation start ups set to enable P4 medicine Leroy Hood’s vision of P4 or ‘systemic’ medicine (preventive, predictive, personalised, participatory) is becoming a reality. By using omics data and medical records to create AI-powered individual health profiles, new automated product innovations aim to target diseases before symptoms even appear, reducing healthcare costs. On the second day of the SLAS 2025 conference, SLAS Ignite […] Written by Thomas Gabrielczyk January 29, 2025January 29, 2025 Saving Bookmark this article Bookmarked
Biotechnology Merry Christmas and a Happy New Year European Biotechnology wishes its readers a Merry Christmas and a Happy New Year! We are taking a short winter break and will be back in January 2025 to provide you with the latest news, background reports, personalia and – in cooperation with our new partner, the Society for Laboratory Automation & Screening (SLAS) – updates […] Written by Thomas Gabrielczyk December 26, 2024December 26, 2024 Saving Bookmark this article Bookmarked
Biotechnology Elevation Oncology Inc licences Synaffix BV’s ADC platform With the US$368m licence deal, Elevation Oncology, Inc is recognising Synaffix’s expertise in ADC development for the development of EO-1022. In contrast to Synaffix’s November deal with the Chinese BigHat Bioscience Co. Ltd, the US company does not book Lonza’s ADC manufacturing services that offers the same quality assurance process for all (clinicla) development phases, […] Written by Thomas Gabrielczyk December 13, 2024December 13, 2024 Saving Bookmark this article Bookmarked
Biotechnology Tetraspecific B/NK cell better than T cell engagers The therapeutic landscape for relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) is evolving toward targeted T-cell based immunotherapies, including CD19-targeted CAR-T and CD3xCD20 T-cell engaging (TCE) bispecificantibodies. Yet, there remains an unmet medical need for patients who are refractory to, or ineligible for these treatments. Leveraging natural killer NK cells emerges as a promising […] Written by Thomas Gabrielczyk November 16, 2024November 16, 2024 Saving Bookmark this article Bookmarked
Biotechnology Sphingotec secures Series C financing Diagnostics company SphingoTec GmbH (Hennigsdorf, Germany) has successful closed a €5m Series C financing round led by Think.Health Ventures, with support from existing investors Brandenburg Kapital, HBM Healthcare Investments, NRW.BANK, and Wellington Partners. The raised capital will allow the company to reach profitability through partnerships and licence deals of its kidney function test penKid and […] Written by Thomas Gabrielczyk August 15, 2024August 15, 2024 Saving Bookmark this article Bookmarked
Biotechnology Gourmey files first EU application for cell-based meat At the time of its EU market authorisation application, Gourmey SAS, which has raised €57.8m so far, has applied for authorisation from the competent authorities in the UK, Switzerland, Singapore and the USA. Ivo Rzegotta, responsible for political communication at GFI Europe interest group, described the application as an important signal for the sector: ‘Cultivated […] Written by Thomas Gabrielczyk July 29, 2024July 29, 2024 Saving Bookmark this article Bookmarked
